peptidylprolyl isomerase A pseudogene 87Genealiases: []
Q-omics provides the consensus-scored PPIAP87 profile across patient tissues and cancer cell-line models. PPIAP87 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PPIAP87 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PPIAP87 RNA expression shows 11,217 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, HNSC, and GBM as cancer lineages where PPIAP87 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP87 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP87 survival associations across molecular data types. PPIAP87 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP87 RNA expression–survival associations across cancer types. High PPIAP87 expression shows unfavorable associations in LIHC, OV, UVM, MESO and PAAD, but favorable associations in CESC. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for PPIAP87 RNA expression.
This table summarizes PPIAP87 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP87. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP87 shows higher tumor expression in HNSC, COAD, STAD, BRCA, LUAD and LIHC. The HNSC box plot shows higher PPIAP87 RNA expression in tumor versus normal tissue (log2 FC = +0.168, t-test p = .001).
This table shows molecular features associated with PPIAP87 in patient tissues and cancer cell lines. In patient samples, PPIAP87 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
